You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on breast cancer.
The study, presented at the NSGC annual conference last week, supports the broader use of panel testing for cancer patients suspected of hereditary disease.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Researchers found that cancer patients with BRCA2 mutations respond particularly well to checkpoint inhibitors compared to those with BRCA1 mutations.
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
The firm is still designing the study, which will explore the ability of GP2 to prevent recurrence in HER2-postive breast cancer after surgery.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
Trodelvy's clinical development in China, led by Everest Medicines, follows the agent's US accelerated approval in April for triple-negative breast cancer.
The Phase III trial will compare Enhertu against Kadcyla as an adjuvant treatment for early-stage HER2-positive breast cancer patients.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.